Hyperoxaluria and systemic oxalosis: current therapy and future directions (Q36613873)

15 August 2017

1 reference

title

Hyperoxaluria and systemic oxalosis: current therapy and future directions (English)

1 reference

15 August 2017

Amy E Bobrowski

1

1 reference

15 August 2017

Craig B Langman

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

14

1 reference

15 August 2017

page(s)

1887-1896

1 reference

Phenotypic expression of primary hyperoxaluria: comparative features of types I and II.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Primary hyperoxaluria--the German experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

The primary hyperoxalurias: an algorithm for diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Clinical implications of mutation analysis in primary hyperoxaluria type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Importance of magnesium in absorption and excretion of oxalate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Oral L-arginine supplementation ameliorates urinary risk factors and kinetic modulation of Tamm-Horsfall glycoprotein in experimental hyperoxaluric rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Management of primary hyperoxaluria: efficacy of oral citrate administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

(L)-2-oxothiazolidine-4-carboxylate in the treatment of primary hyperoxaluria type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Oxalate clearance by haemodialysis--a comparison of seven dialysers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Long daily hemodialysis sessions correct systemic complications of oxalosis prior to combined liver-kidney transplantation: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Transplantation for primary hyperoxaluria in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): the European PH1 transplant registry experience 1984-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Combined liver-kidney transplantation in primary hyperoxaluria type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Renal allograft survival in patients with oxalosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Long term results of liver-kidney transplantation in children with primary hyperoxaluria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Primary hyperoxaluria type 1: improved outcome with timely liver transplantation: a single-center report of 36 children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Combined liver-kidney transplantation for primary hyperoxaluria type 1 in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Results of simultaneous and sequential pediatric liver and kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Sequential liver-kidney transplantation from a living-related donor in primary hyperoxaluria type 1 (oxalosis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Primary hyperoxaluria: simultaneous combined liver and kidney transplantation from a living related donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Cadaveric orthotopic auxiliary split liver transplantation and kidney transplantation: an alternative for type 1 primary hyperoxaluria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Use of a probiotic to decrease enteric hyperoxaluria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Correction of an enzyme trafficking defect in hereditary kidney stone disease in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Crystal structure of alanine:glyoxylate aminotransferase and the relationship between genotype and enzymatic phenotype in primary hyperoxaluria type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Limitation of apoptotic changes in renal tubular cell injury induced by hyperoxaluria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Mitochondrial hydroxyproline metabolism: implications for primary hyperoxaluria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

Cellular transfection to deliver alanine-glyoxylate aminotransferase to hepatocytes: a rational gene therapy for primary hyperoxaluria-1 (PH-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.14.1887

10.1517/14656566.7.14.1887

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference